Screener
Hemab Therapeutics Holdings, Inc. COAG Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | $20,336 | $12,874 | $39,797 | $26,975 |
| General and administrative | 5,743 | 3,183 | 9,894 | 5,642 |
| Total operating expenses | 26,079 | 16,057 | 49,691 | 32,617 |
| Loss from operations | (26,079) | (16,057) | (49,691) | (32,617) |
| Other income (expense), net | ||||
| Interest income | 2,858 | 335 | 4,077 | 808 |
| Other (expense) income, net | (832) | 3,517 | (1,114) | 4,108 |
| Total other income, net | 2,026 | 3,852 | 2,963 | 4,916 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s operating income?
- Hemab Therapeutics Holdings, Inc. (COAG) reported operating income of -$26.08M in Q2 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude